VFC and VFAAR Flu Vaccine Now Available to Order


  1. Fax in temperature logs since the last time your site ordered any vaccine up to the day you’re submitting the order
  2. Log onto KIDS Plus IIS at http://kids.phila.gov/
  3. Complete an initial reconciliation for flu (subsequent flu orders will only require a reconciliation completed within 60 days of your flu order)
  4. Check the “Will this be an influenza order?” box on the vaccine order page
  5. Order only what your site needs for a 4 to 6 week period
  6. Order only what you can store in your refrigerator
  7. Check the status of your order 2 business days later in KIDS Plus IIS to see if your order has been processed
  8. Check the VFC or VFAAR “Program Comments” section of your order screen to receive any notes regarding your order entry

PDPH will make every effort to fulfill your complete flu vaccine request; however, in the event that flu product is available in limited quantity, PDPH will reduce your order and notify you via the KIDS Plus IIS comment box.

Continue ordering flu vaccine throughout the season as needed. Keep vaccinating until product expires. Only use VFC vaccine to vaccinate VFC eligible patients (0-18 years and are uninsured, Medicaid, Native American/Alaska Native).

Flu vaccine may typically arrive separately from other vaccines even if flu and non-flu vaccines are ordered at the same time. The day you receive your flu order, log into KIDS Plus IIS and electronically receive the doses via the Pending VTrckS Shipment link from your On-Hand page. If you receive a vaccine shipment with an out-of-range temperature monitoring reading, please contact the Immunization Program immediately.

The latest VISs.

Download the VFC message here.

Download the VFAAR message here.


Paper Order Providers

Most providers order VFC and VFAAR vaccine through KIDS Plus IIS. If you still order with paper forms your process is a little different. Please read the following messages and follow the instructions. This is for authorized paper order providers only.

Download the VFC paper ordering message here.

Download the VFAAR paper ordering message here.

VFC Inventory Form

VFAAR Inventory Form

MenB Vaccines and VFC

New MenB Vaccines

The VFC Program now offers the two recently licensed meningococcal B vaccines, Bexsero®, manufactured by GlaxoSmithKline, and Trumenba®, manufactured by Pfizer Inc.

Meningococcal Group B Vaccines (MenB)

Both Bexsero® and Trumenba® are recombinant vaccines licensed in the United States for prevention of meningococcal serotype B disease in indicated persons 10 – 25 years of age. Meningococcal disease is a life-threatening illness caused by bacteria that can cause sepsis and meningitis. Thirteen different meningococcal serogroups have been defined, five of which cause the great majority of disease (A, B, C, Y, and W135). According to the CDC, approximately 500 total cases of meningococcal disease were reported in the U.S. in 2012, of which 160 (32%) were caused by serogroup B. The majority of the other cases of meningococcal disease were caused by the serogroups A, C, Y, and W135. Invasive disease with these 4 serogroups are preventable by meningococcal conjugate quadrivalent vaccines (MCV4; Menactra®, Sanofi Pasteur; Menveo®, GlaxoSmithKline), which have been supplied by VFC for many years.

The Philadelphia VFC Program will supply either of the two vaccines to VFC providers – at their choice – for VFC-eligible, medically-indicated patients 10 – 18 years of age, as detailed below.

Recommendations for Use of MenB Vaccines for VFC-Eligible Children

MenB should be administered to children 10 – 15 years of age at increased risk of meningococcal disease, due to one of the following:

  1. Children 10 – 15 years of age with persistent complement component deficiencies;
  2. Children 10 – 15 years of age with anatomic or functional asplenia;
  3. Children 10 – 15 years of age at risk because of a serogroup B meningococcal outbreak.

MenB may be administered to children 16 – 18 years of age who are determined to be at increased risk of meningococcal type B disease.

Administration of MenB Vaccines

Bexsero® vaccine is licensed as a two-dose schedule, given at least 28 days apart, i.e., at 0 and 1 month. Trumenba® vaccine is licensed as a three-dose schedule, given at 0, 1 – 2 months, and 6 months. Both Bexsero® and Trumenba® are supplied in 0.5 mL prefilled syringes, to be administered via intramuscular injection into the deltoid muscle of the upper arm. If vaccine is administered at intervals longer than recommended, there is no need to restart the series. Each MenB vaccine can be administered at the same visit as all other indicated vaccines.

Read the PDF here.

Returning VFC/VFAAR Influenza Vaccine

Return All Unopened VFC/VFAAR Influenza Vaccine

All VFC and VFAAR 2014-15 seasonal flu vaccine expired June 30, 2015. These doses should be reported to the Philadelphia Immunization Program by July 31, 2015.

Reporting Flu Vaccine

If you order VFC/VFAAR vaccines online, you should now report the expiring flu vaccines online in KIDS Plus IIS. Register for vaccine returns training on this web form: http://goo.gl/forms/fkQIpsfr5r

If you order vaccines via paper logs, you should report these vaccines using the “Wasted” form for opened vials, and “Expired/Spoiled” form for unopened vials. Fax these forms to 215-238-6939. Discard the wasted vaccine, and set aside the expired/spoiled vaccine.

Read the full message here.

VFC Program: 9-valent HPV Vaccine

Philadelphia VFC Program

Beginning July 1, 2015, the Philadelphia Vaccines For Children (VFC) Program will cutover entirely to supplying the recently licensed recommended 9-valent human papillomavirus (9vHPV) GARDASIL®9 vaccine to replace the currently supplied 4-valent human papillomavirus (4vHPV) GARDASIL®4 vaccine. Both vaccines are manufactured by Merck, Sharpe and Dohme Corp.

Read the full message here.

Recommended 9vHPV Vaccine Immunization

The ACIP recommended 9vHPV for routine vaccination at 11-12 year for males and females. Catch-up vaccination is recommended for females 13-26 years and males up to 21 years and up to 26 years for MSM and immunocompromised males. The ACIP recommendation overrides the FDA approval.

Starting July 1, the Philadelphia VFC Program will no longer offer 4vHPV. That product will be replaced with 9vHPV. The 9vHPV vaccine follows the same recommended immunization schedule as 4vHPV.

For more information please read the March 27, 2015 ACIP recommendations published in the CDC’s MMWR.

Annual Program Re-enrollment

Vaccines for Children (VFC)

All VFC providers must complete the annual VFC Re-enrollment Forms. Please read and complete the re-enrollment forms by Friday, July 10, 2015.

Vaccines for Adults at Risk (VFAAR)

All VFAAR providers must complete the annual VFAAR Re-enrollment Forms. Please read and complete the re-enrollment forms by Friday, July 10, 2015.


Please complete the KIDS Plus IIS Confidentiality Agreement and return it by Friday, July 10, 2015.

2015 New Year Immunization Update

This Immunization Update includes information on:

  • Required back-up thermometers
  • Data loggers
  • Provider survey
  • New wastage module in KIDS Plus IIS
  • Annual VFC and VFAAR enrollment
  • KIDS Plus IIS upgrade
  • New ACIP recommended immunization schedules
  • New Immunization Program staff
  • Education materials
  • Wastage policy reminder

Read the full Immunization Update here.

Immz Program PDPH Logo - blue - small - 72 ppi


Mailing Address

PDPH Immunization Program

500 South Broad Street

2nd Floor

Philadelphia, PA 19146


KIDS Plus IIS Hotline

Email: KIDSRegistry@phila.gov

Phone: 215-685-6784


Hours of Operation

8:30 am to 5:00 pm

Monday to Friday

(except city holidays)